Olema Pharmaceuticals, Inc. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib…OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

   Enrollment closed, study ongoing

   Olema Pharmaceuticals, Inc.·Phase 1· NCT05508906· Registry history of NCT05508906 on ClinicalTrials.gov (opens the registry)

   Updated Sep 15, 2026

2. Minor

   OP-3136 in Advanced or Metastatic Solid Tumors

   Trial sites expanded: 8 → 25 locations

   Olema Pharmaceuticals, Inc.·Phase 1· NCT06784193· Registry history of NCT06784193 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

3. Minor

   OPERA-02 · Palazestrant in Combination With Ribociclib for the…OPERA-02 · Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

   Trial sites expanded: 181 → 200 locations

   Olema Pharmaceuticals, Inc.·Phase 3· NCT07085767· Registry history of NCT07085767 on ClinicalTrials.gov (opens the registry)

   Updated Sep 23, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.